ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OGN Organon and Co

20.94
0.37 (1.80%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Organon and Co NYSE:OGN NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.37 1.80% 20.94 21.01 20.52 20.60 1,782,985 01:00:00

Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023

17/07/2023 12:30pm

Business Wire


Organon (NYSE:OGN)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Organon Charts.

Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://events.q4inc.com/attendee/930696972.

Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram,Twitter and Facebook.

Organon Media Karissa Peer (614) 314-8094 Kate Vossen (732) 675-8448 Organon Investors Jennifer Halchak (201) 275-2711 Alex Arzeno (203) 550-3972

1 Year Organon Chart

1 Year Organon Chart

1 Month Organon Chart

1 Month Organon Chart